Document Detail


Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence.
MedLine Citation:
PMID:  17593230     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Atrial fibrillation and atrial flutter often coexist. The long-term occurrence of atrial fibrillation in patients presenting with atrial flutter alone is unknown. We report the long-term follow-up in patients who underwent cavotricuspid isthmus ablation for treatment of lone atrial flutter. METHODS AND RESULTS: Between January 1997 and June 2002, 632 patients underwent cavotricuspid isthmus ablation for the treatment of typical atrial flutter at the Cleveland Clinic Foundation. Three hundred sixty-three patients were included in this study and followed for a mean duration of 39 +/- 11 months. The mean duration of atrial flutter symptoms was 12 +/- 5 months. Mean left-atrial size and left-ventricular ejection fraction were 4.2 +/- 0.8 cm and 47 +/- 13%, respectively. After a mean follow-up time of 39 +/- 11 months, 13% (48 of 363) of the patients remained in sinus rhythm. Five percent (18 of 363) of patients experienced recurrence of atrial flutter only. Sixty-eight percent (246 of 363) experienced the onset of atrial fibrillation and 14% (51 of 363) experienced recurrence of atrial flutter and the new onset of atrial fibrillation. Overall, 82% (297 of 363) of the patients experienced new onset of drug refractory atrial fibrillation. Left-atrial size was a predictor of atrial fibrillation recurrence post-atrial flutter ablation. CONCLUSION: At long-term follow-up, approximately 82% of patients post-cavotricuspid isthmus ablation for atrial flutter developed drug refractory atrial fibrillation. This finding suggests that elimination of atrial flutter might delay, but does not prevent, atrial fibrillation. Evidence suggests both arrhythmias may share common triggers and such patients may derive a better long-term benefit from anatomical ablative treatment of atrial fibrillation as well.
Authors:
Keith Ellis; Oussama Wazni; Nassir Marrouche; David Martin; Marc Gillinov; Patrick McCarthy; Eduardo B Saad; Mandeep Bhargava; Robert Schweikert; Walid Saliba; Dianna Bash; Antonio Rossillo; Demet Erciyes; Patrick Tchou; Andrea Natale
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2007-06-25
Journal Detail:
Title:  Journal of cardiovascular electrophysiology     Volume:  18     ISSN:  1540-8167     ISO Abbreviation:  J. Cardiovasc. Electrophysiol.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-26     Completed Date:  2007-09-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9010756     Medline TA:  J Cardiovasc Electrophysiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  799-802     Citation Subset:  IM    
Affiliation:
Center for Atrial Fibrillation, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Arrhythmia Agents / therapeutic use
Atrial Fibrillation / diagnosis*,  drug therapy,  epidemiology*
Atrial Flutter / epidemiology*,  surgery*
Catheter Ablation / statistics & numerical data*
Comorbidity
Female
Heart Atria / pathology*
Humans
Incidence
Male
Middle Aged
Ohio / epidemiology
Prognosis
Recurrence
Reproducibility of Results
Risk Assessment / methods*
Risk Factors
Sensitivity and Specificity
Tricuspid Valve / surgery
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Radiofrequency ablation of infarct scar-related ventricular tachycardia: correlation of electroanato...
Next Document:  Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrh...